Neuren Pharmaceuticals Limited (ASX:NEU)
Australia
· Delayed Price · Currency is AUD | Market Cap | 1.51B |
| Revenue (ttm) | 64.65M |
| Net Income (ttm) | 30.44M |
| Shares Out | 126.45M |
| EPS (ttm) | 0.23 |
| PE Ratio | 51.27 |
| Forward PE | 93.33 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 346,198 |
| Average Volume | 299,440 |
| Open | 12.08 |
| Previous Close | 12.20 |
| Day's Range | 11.68 - 12.12 |
| 52-Week Range | 10.92 - 22.99 |
| Beta | 1.58 |
| RSI | 40.40 |
| Earnings Date | May 29, 2026 |
About Neuren Pharmaceuticals
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develo... [Read more]
Financial Performance
In 2025, Neuren Pharmaceuticals's revenue was 64.65 million, a decrease of -70.18% compared to the previous year's 216.83 million. Earnings were 30.44 million, a decrease of -78.57%.
Financial StatementsNews
Neuren Pharmaceuticals Transcript: Investor update
A new share buyback of up to 5% was approved, reflecting strong financials and confidence in future growth. Key clinical programs for PMS, Pitt Hopkins, and HIE are prioritized, with PMS phase III now underway and additional studies targeted for late 2024. Management remains focused on orphan indications and sees recent share price volatility as disconnected from fundamentals.
Neuren Pharmaceuticals Transcript: AGM 2025
Record financial results and strong DAYBUE sales underpin robust cash reserves, enabling global expansion and advancement of NNZ-2591 into pivotal trials. Strategic focus remains on pipeline growth, prudent capital management, and addressing market volatility, with ongoing shareholder engagement and governance updates.
Neuren Pharmaceuticals Earnings Call Transcript: H2 2024
Record comprehensive income of AUD 166 million and strong cash position were driven by DAYBUE royalties and milestone payments, with significant global growth opportunities ahead. NNZ-2591 phase three preparations are underway, and the company remains focused on disciplined capital allocation and long-term value creation.
Neuren Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025
Focused on neurodevelopmental disorders, the company leverages strong Daybue sales and global expansion to fund NNZ-2591, which has shown promising phase II results. Royalties, milestone payments, and new indications drive a robust financial outlook.
Neuren Pharmaceuticals Transcript: Study Result
Positive FDA feedback enables a pivotal phase III trial for Phelan-McDermid Syndrome, with final efficacy endpoints pending further data submission. The trial design is set, manufacturing is on track, and robust funding supports execution, while additional indications and regulatory milestones are anticipated.
Neuren Pharmaceuticals Transcript: Study Result
Phase 2 results for NNZ-2591 in Angelman syndrome showed the drug was safe, well-tolerated, and led to clinically meaningful improvements in communication, motor skills, behavior, and cognition, especially in younger children. The company is evaluating phase 3 plans amid a competitive landscape and strong multi-indication validation.